Annexon, Inc. (NASDAQ:ANNX) Short Interest Update

Annexon, Inc. (NASDAQ:ANNX) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 8,980,000 shares, an increase of 23.7% from the December 31st total of 7,260,000 shares. Based on an average daily volume of 1,340,000 shares, the short-interest ratio is presently 6.7 days.

Institutional Trading of Annexon

Several hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its stake in Annexon by 4.3% during the 4th quarter. Rhumbline Advisers now owns 141,852 shares of the company’s stock worth $728,000 after buying an additional 5,854 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Annexon during the 4th quarter worth about $116,000. Hennion & Walsh Asset Management Inc. increased its holdings in Annexon by 65.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 429,584 shares of the company’s stock worth $2,204,000 after purchasing an additional 170,180 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Annexon by 16.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock worth $10,101,000 after purchasing an additional 235,810 shares in the last quarter. Finally, Franklin Resources Inc. bought a new position in Annexon during the 3rd quarter worth about $292,000.

Annexon Stock Down 1.4 %

Annexon stock traded down $0.06 during mid-day trading on Friday, hitting $3.99. 567,502 shares of the company’s stock were exchanged, compared to its average volume of 1,505,372. The firm has a market capitalization of $424.76 million, a P/E ratio of -3.80 and a beta of 1.11. Annexon has a fifty-two week low of $3.82 and a fifty-two week high of $8.40. The company’s 50 day simple moving average is $4.85 and its 200-day simple moving average is $5.86.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Annexon in a report on Tuesday, December 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.